SCHEMBL505264

SCHEMBL505264

N#Cc1ccc(Oc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 2/20 0.71
PARP10 Q53GL7 2/20 0.71
PARP2 Q9UGN5 1/20 0.71
MAPT P10636 2/20 0.59
PKM P14618 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MEN1 O00255 1/20 0.59
LMNA P02545 1/20 0.59
POLB P06746 1/20 0.59
MAPK1 P28482 1/20 0.59
RAB9A P51151 1/20 0.59
KMT2A Q03164 1/20 0.59
IL18 Q14116 1/20 0.59
SRD5A2 P31213 4/20 0.56
ALDH1A1 P00352 1/20 0.53
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
MMP2 P08253 1/20 0.47
GSK3B P49841 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28781661 0.93 PARP10 (0.63) PARP15PARP10PARP2MAPTPKM
SCHEMBL851979 0.89 PARP15 (0.62) PARP15PARP10PARP2MAPTPKM
SCHEMBL216706 0.88 CA2 (0.64) PARP15PARP10PARP2MAPTSRD5A2
SCHEMBL11796934 0.86 PARP15 (0.73) PARP15PARP10PARP2MAPTPKM
SCHEMBL28435413 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2
SCHEMBL11453092 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2
SCHEMBL15347438 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2
Ammonia Solution, Strong SCHEMBL22265084 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2
SCHEMBL27765473 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2
Hydrochloric Acid SCHEMBL3184981 0.86 CA2 (0.61) PARP15PARP10PARP2MAPTSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025104079-A1 SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-05-22 WO disclosed
CN-115536586-B Pyrazole amide compound as well as preparation method and application thereof 华东理工大学 2024-08-09 CN disclosed
CN-111868055-B Inhibitors of TRPC6 勃林格殷格翰国际有限公司 2024-03-08 CN disclosed
CN-115536586-A Pyrazole amide compounds and preparation method and application thereof 华东理工大学 2022-12-30 CN disclosed
US-11370771-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-06-28 US disclosed
US-11370771-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-06-28 US disclosed
US-20210053935-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-02-25 US disclosed
US-20210053935-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-02-25 US disclosed
EP-3752503-A1 INHIBITORS OF TRPC6 Boehringer Ingelheim International GmbH (DE) 2020-12-23 EP disclosed
CN-111868055-A Inhibitors of TRPC6 勃林格殷格翰国际有限公司 2020-10-30 CN disclosed
US-20070112049-A1 nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria ARMY, UNITED STATES 2007-05-17 US disclosed
US-7041684-B2 Selective β3 adrenergic agonists ELI LILLY AND COMPANY (US) 2006-05-09 US disclosed
US-20050043337-A1 Selective beta3 adrenergic agonists RITO CHRISTOPHER J (US) 2005-02-24 US disclosed
US-6686372-B2 ANTIDIABETIC AGENTS; DIETETICS ELI LILLY AND COMPANY 2004-02-03 US disclosed
US-20020165234-A1 Selective B3 adrenergic agonists CROWELL THOMAS A (US) 2002-11-07 US disclosed
US-6413991-B1 ANTIDIABETIC AGENTS; DIETETICS ELI LILLY AND COMPANY 2002-07-02 US disclosed
EP-0827746-B1 Carbazole analogues as selective beta3 adrenergic agonists LILLY CO ELI (US) 2002-04-03 EP disclosed
US-6140352-A FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY ELI LILLY AND COMPANY (US) 2000-10-31 US disclosed
WO-1998009625-A1 SELECTIVE β3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 1998-03-12 WO disclosed
EP-0827746-A1 Carbazole analogues as selective B3 adrenergic agonists ELI LILLY AND COMPANY (US) 1998-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210053935-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC4 PARP15 978/4885PARP10 104/4885PARP2 3005/4885
US-20050043337-A1 Selective beta3 adrenergic agonists ADRB3, ADRB2, ADRB1 PARP15 2301/4885PARP10 3439/4885PARP2 3174/4885
US-20070112049-A1 nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria ACHE, CTRL, MMP2 PARP15 1217/4885PARP10 2054/4885PARP2 2462/4885
US-20020165234-A1 Selective B3 adrenergic agonists ADRB3, ADRB2, ADRB1 PARP15 2163/4885PARP10 2906/4885PARP2 3426/4885
US-11370771-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC4 PARP15 978/4885PARP10 104/4885PARP2 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.